Impact of diabetes on outcomes in hypertrophic cardiomyopathy: a GRADE meta-analysis Authors: Seyedeh-Tarlan Mirzohreh, Niloofar Deravi, Elnaz Javanshir, Mohammad Asghari Jafarabadi, Neda Roshanravan Published: 2026 ABSTRACT AbstractBackgroundDiabetes mellitus (DM) is a common comorbidity in hypertrophic cardiomyopathy (HCM) and may exacerbate arrhythmic risk, promote structural remodelling and worsen heart failure outcomes. Its overall prognostic impact and effect on cardiac structure and function in adults with HCM remain uncertain.MethodWe systematically searched PubMed, Scopus, Web of Science and Cochrane to January 2025 for observational studies comparing adults with HCM-DM versus HCM without DM. Random-effects meta-analyses were performed to pool ORs for clinical outcomes and standardised mean differences (SMDs) for echocardiographic parameters. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework after Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) evaluation. Subgroup, sensitivity and heterogeneity analyses were undertaken.ResultEight studies encompassing approximately 47 592 patients met inclusion criteria. DM was associated with higher odds of all-cause mortality (OR 1.43, 95% CI 1.29 to 1.58; high certainty), heart failure (OR 1.34, 95% CI 1.25 to 1.43; moderate certainty) and atrial fibrillation (OR 1.41, 95% CI 1.18 to 1.68; high certainty). The association with atrial fibrillation was most pronounced in patients younger than 50 years (OR 2.55) and attenuated in those with body mass index ≥30 kg/m². HCM-DM was also linked to smaller left ventricular end-diastolic volumes (SMD −0.26) and impaired global longitudinal strain (SMD 0.58), consistent with subclinical systolic dysfunction, although heterogeneity was high and certainty low to moderate. Evidence for left ventricular ejection fraction, mass and septal thickness was inconclusive. Results were robust across sensitivity analyses.ConclusionsDM is a clinically important risk marker in HCM, associated with excess mortality, heart failure and atrial fibrillation, as well as adverse structural–functional changes. These findings support closer rhythm and function monitoring in HCM-DM and highlight the need for prospective studies to determine whether targeted metabolic interventions can improve outcomes.PROSPERO registration numberCRD420250650799. WHAT IS ALREADY KNOWN ON THIS TOPIC Diabetes mellitus (DM) is a common comorbidity in patients with hypertrophic cardiomyopathy (HCM), and both conditions independently increase the risk of adverse cardiovascular outcomes. Diabetes mellitus (DM) is a common comorbidity in patients with hypertrophic cardiomyopathy (HCM), and both conditions independently increase the risk of adverse cardiovascular outcomes. Previous observational studies have suggested that DM may exacerbate heart failure, arrhythmias, and mortality in HCM, but results have been inconsistent, particularly regarding cardiac structural and functional parameters. Previous observational studies have suggested that DM may exacerbate heart failure, arrhythmias, and mortality in HCM, but results have been inconsistent, particularly regarding cardiac structural and functional parameters. No prior meta-analysis has comprehensively evaluated both clinical outcomes and cardiac function in HCM-DM compared with HCM alone.ne. No prior meta-analysis has comprehensively evaluated both clinical outcomes and cardiac function in HCM-DM compared with HCM alone.ne. WHAT THIS STUDY ADDS This systematic review and GRADE-based meta-analysis synthesizes current evidence to assess the impact of DM on both clinical outcomes and cardiac function in HCM. This systematic review and GRADE-based meta-analysis synthesizes current evidence to assess the impact of DM on both clinical outcomes and cardiac function in HCM. DM is associated with significantly higher odds of all-cause mortality, heart failure, and atrial fibrillation, with the association with atrial fibrillation being particularly pronounced in younger and non-obese patients. DM is associated with significantly higher odds of all-cause mortality, heart failure, and atrial fibrillation, with the association with atrial fibrillation being particularly pronounced in younger and non-obese patients. Imaging analyses demonstrate smaller left ventricular end-diastolic volumes (LVEDV) and impaired global longitudinal strain (LV-GLS) in HCM-DM, indicating subclinical systolic dysfunction despite preserved ejection fraction. Imaging analyses demonstrate smaller left ventricular end-diastolic volumes (LVEDV) and impaired global longitudinal strain (LV-GLS) in HCM-DM, indicating subclinical systolic dysfunction despite preserved ejection fraction. These associations were consistent across multiple sensitivity analyses, with high certainty of evidence for major clinical outcomes.mes. These associations were consistent across multiple sensitivity analyses, with high certainty of evidence for major clinical outcomes.mes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Recognition of DM as an important risk marker in HCM supports closer rhythm and function surveillance, incorporation of DM into risk stratification models, and consideration of targeted metabolic interventions to potentially improve outcomes. Recognition of DM as an important risk marker in HCM supports closer rhythm and function surveillance, incorporation of DM into risk stratification models, and consideration of targeted metabolic interventions to potentially improve outcomes. Future research should investigate whether intensive metabolic management can modify the trajectory of HCM in patients with DM. Future research should investigate whether intensive metabolic management can modify the trajectory of HCM in patients with DM. Introduction Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and a major cause of sudden cardiac death in young adults.1 Diabetes mellitus (DM) affects over 10% of adults worldwide and is increasingly recognised as a modifier of cardiovascular disease outcomes. When coexistent, these two conditions may interact through additive metabolic, structural and microvascular stress, potentially worsening the prognosis of HCM.2 Several cohort studies have reported that patients with HCM with DM experience higher rates of adverse events, including mortality, heart failure (HF) and arrhythmias, as well as structural and functional cardiac changes.3–10 However, findings are inconsistent, particularly for measures such as left ventricular ejection fraction, mass and strain. Some studies are limited by small sample sizes, single-centre design, heterogeneous imaging protocols and varying definitions of outcomes. In addition, clinical and imaging endpoints have rarely been assessed together in a unified analysis. No prior meta-analysis has comprehensively integrated both clinical outcomes and imaging parameters in this population. Therefore, in this systematic review and meta-analysis, we aimed to synthesise current evidence on the impact of DM on cardiac function and clinical outcomes in adults with HCM, and to assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Methods We adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines11 (online supplemental S1) and registered the protocol in PROSPERO (CRD420250650799). The study was designed according to the Population, Intervention, Comparison, and Outcome (PICOs) framework. Eligibility criteria We included observational studies of adults with HCM, diagnosed using standard imaging criteria, that compared those with and without DM and reported clinical outcomes and/or echocardiographic or cardiac MRI parameters. Studies involving non-genetic hypertrophy, other cardiomyopathy types, paediatric populations or interventional designs were excluded. The full eligibility criteria are provided in online supplemental S2. Information sources We searched PubMed, Scopus, Web of Science and Cochrane from inception to January 2025 without language restrictions. Manual searches of reference lists from eligible articles were also performed. Search strategy The database search strategy was developed with a medical librarian to ensure comprehensiveness and reproducibility. For example, the Scopus search used the following query: (TITLE-ABS-KEY (“Diabetes Mellitus” OR “insulin resistance” OR “hyperglycemia” OR diabet* OR prediabet* OR “Glycated hemoglobin A” OR hyperinsulinemia OR glycemi*)) AND (TITLE-ABS-KEY (“hypertrophic cardiomyopathy” OR “obstructive cardiomyopathy” OR “idiopathic hypertrophic sub aortic stenosis” OR “asymmetric septal hypertrophy” OR “hypertrophic heart disease” OR “muscular subaortic stenosis” OR “septal hypertrophy” OR “HCM”)). Detailed search strings for PubMed, Web of Science and Cochrane are provided in online supplemental S2. Study selection and data extraction Two reviewers independently screened titles/abstracts and extracted data on study design, population characteristics, outcomes and imaging findings, resolving discrepancies by consensus. Risk of bias and outcome quality assessment We used the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool12 to assess risk of bias and graded the certainty of evidence using the GRADE framework.13 Detailed criteria for ROBINS-I scoring and GRADE upgrading/downgrading rules are in online supplemental S2. Statistical analysis Effect sizes were pooled as standardised mean differences (SMD) or ORs with 95% CIs using a random-effects model. Heterogeneity was assessed with the I² statistic (25%, 50% and 75% representing low, moderate and high levels, respectively). For I²≥50%, sensitivity analyses were performed by sequentially excluding studies, and subgroup analyses were conducted according to clinically relevant factors (eg, age, body mass index (BMI)). Robustness was evaluated using the ‘one study removed’ method. Publication bias was assessed via funnel plots, Begg’s test and Egger’s test. All analyses were performed using Comprehensive Meta-Analysis, V.3 (Biostat, New Jersey, USA), with p<0.05 considered statistically significant. Results Study selection The study flowchart is shown in figure 1; our search strategy revealed 561 studies in PubMed, 1333 in Scopus, 784 in Web of Science and 55 in Cochrane. After removing duplications, 2142 studies underwent title assessment. Of these, 196 studies were eligible for abstract review. After surveying abstracts, 12 studies were perused for full text. Finally, 8 studies were qualified to be included in this systematic review and meta-analysis, and the rest did not meet the inclusion criteria. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram presenting results of search and screening strategy in databases. Characteristics of studies Eight studies3–10 involving 47 592 patients with HCM, with or without DM, were included from Egypt, China, the UK, the USA, Korea, Spain and Israel. Designs included prospective and retrospective cohorts, with sample sizes ranging from 20 patients with HCM-DM (Jex et al5) to 14 279 (Hajouli et al4), and follow-up from 2 to 10 years. Participants’ mean ages ranged from 45 to 70 years; most studies reported higher BMI in HCM-DM than HCM-only groups. DM duration was reported in only two studies (mean 10.7±6.6 years in Badran et al3 and >5 years in Lee et al6). Cardiac function was primarily assessed by echocardiography, with one study using Cardiac magnetic resonance (CMR).5 Analyses of mortality, hospitalisation, HF and atrial fibrillation (AF) showed substantial heterogeneity by study type and patient characteristics (table 1). Table 1Included studies’ characteristicsFirst author, year, population source (country), study designSample size (case/control)FUD, age (years), BMIDiabetes duration (year)Cardiac function(echo, CMR)Clinical outcomesOther findingsMatched covariates between groupsExclusion criteria Badran et al 2024 (3)EgyptProspective cohort 47/372 Obstructive phenotype prevalence: 20% in isolated HCM vs 29% in HCM-DM (no significant difference)FUD:68.7 months (5.6 years)AgeHCM-DM: 47±17HCM: 44±14BMI:Not reportedDiabetes duration:10.7±6.6 years Significant ↓ E’ wave in HCM-DM compared with HCM group.Significant ↓LV-GLS (less negative) in HCM-DM compared with HCM.Significant ↓LV peak systolic global strain rate (less negative) in HCM-DM compared with HCM.Significant ↓peak atrial diastolic and ↓LV early diastolic strain rate in HCM-DM compared with HCM. ↑Mortality rate:HCM-DM: 10.6%,HCM: 7.5%(no significant difference) Significant ↑hospitalisation rate in HCM-DM (44.7%) compared with HCM (19.5%) LV-GLS, LV peak systolic global strain rate and peak atrial diastolic strain rate in HCM-DM were inversely correlated to HbA1c and duration of diabetes. Matched: Age, sex, BP, baseline HR, familial HCM, NYHA function class, HCM phenotypeUnmatched: HTN was significantly higher in HCM-DM than HCM group. Poor acoustic window, other myocardium disease, arrhythmia, previous cardiac surgery, cardiac devices, valvular heart disease and evidence of CAD. Wang et al 2024 (8)ChinaRetrospective cohort 75/150 All patients have Obstructive-HCM.FUD:Ranged from four to 14 years.(Patient selection is between 2011–2020)AgeHCM-DM: 45.9±17.8HCM: 45.6±15.9BMI:HCM-DM: 25.0±4.1-HCM: 25.4±4.1Diabetes duration: NR Prevalence of LAD>45mm:HCM-DM: 45.3%HCM: 33.3% (no significant difference) Significant ↑LVOT pressure gradient in HCM-DM compared with HCM. ↑Prevalence of NSVT, SVT and AF in HCM-DM compared with HCM. ↑FBS and HbA1C in patients with SVT, NSVT and AF compared with HCM-DM without arrhythmias.T2DM, IVST and symptom of amaurosis were independent risk factors for SVT after adjusting for age, sex and BMI.T2DM and LAD>45 mm were independent risk factors for AF after adjusting for age, sex and BMI. T2DM and history of syncope were independent risk factors for NSVT after adjusting for age, sex and BMI. Matched: Age, sex, BMI, baseline HR, serum BNP, serum creatine, hyperlipidaemia, HTN, medicationUnmatched: familial HCM and GFR* Not mentioned Hajouli et al 2024 (4)TriNetX databaseRetrospective cohort 14,279/14 279FUD:5-year time frame (2018–2023).AgeHCM-DM: 64±15HCM: 62±14BMI:HCM-DM: 32.1±7.2HCM: 29.1±6.7Diabetes duration: NR Significant ↓LVEF in HCM-DM compared with HCM group.Non-significant ↑LAD in HCM-DM compared with HCM group. Significant ↑mortality rate inHCM-DM (13.6%) compared withHCM (9.37%).Significant ↑incidence of new-onset HF in HCM-DM (15.85%) compared with HCM (12.36%).AF rate:HCM-DM: 18.58%HCM: 18.57%(not significant difference)Survival analysis against theoutcome of new-onset HF was 79.60% for HCM and 74.47% for HCM-DM groups.Matched: Sex, COPD, ESRD, HTN, CAD, Smoking, familial HCM, familial history of SCD, PH, arrhythmias, medication, GFRUnmatched:Age (patients with HCM-DM were significantly younger; mean 62 vs mean 64 years old), BMI (patients with HCM-DM had higher BMI compared with HCM group).Patients with mitraland/or aortic valve stenosis and exclusion criteria for HCM without DM were presence of any diabetes type or diabetic medication. Yu et al2024 (7)ChinaRetrospective cohort 45/45FUD:10-year time frame (2012–2022)AgeHCM-DM: 62±10HCM: 61±10BMI:HCM-DM: 25.8±2.7-HCM: 24.2±3.1Diabetes duration: NR Significant ↓LVEDV, ↓SV, ↓LVEF, ↓CO, ↓LV-GLS, ↓LV-GRS, ↓LV-GCS, ↓LA-reservoir strain, ↓LA peak positive strain rate, ↓LA conduction function volume in HCM-DM compared with HCM group.↑LGE in HCM-DM compared with HCM group. Significant ↑prevalence of AF in HCM-DM (18%) compared with HCM (9%). Comorbidity with T2DM was significantly associated with ↓LVEF, ↓GRS, ↑GCS, ↑GLS, ↓LA-reservoir strain and ↓LA peak positive strain rate. T2DM was an independent predictor of a low LVEF impaired LV-GLS. Matched: Maximal wall thickness,age, and gender, hyperlipidaemia, GFR, pro-BNP, ACEi/ARB, BB, Familial history of SCD and HCMUnmatched:BMI (both groups are<26 kg/m2), use of CCB, diuretics and statins (HCM-DM>HCM)A history of MI, significant coronary arterial stenosis (≥ 50%) on invasive CAG or CTAHistory of septal reduction therapy;Concomitant uncontrolledHTN; congenital heart diseases; infiltrativecardiomyopathies, severe valvular heart diseases, persistent AF; and uninterpretable CMR images. Jex et al 2022 (3)UKProspective cohort 20/18FUD: 2 yearsAgeHCM-DM: 64±9HCM: 59±10BMI:HCM-DM: 32±6HCM: 29±5Diabetes duration: NR Significant ↑LVM, ↑LVMI, ↑LVM/LVEDV ratio, ↑LVPWT, ↑LA volume in HCM-DM compared with HCM group.Significant ↓LVESV, ↓LV-SV, ↓RV-SV, ↓LVEF, ↓LV-GLS, ↓ Peak circumferential diastolic strain rate in HCM-DM compared with HCM group. Significant ↑prevalence of stroke (TIA) in HCM-DM compared with HCM group.HF in isolated HCM:83% NYHA-I, 17% NYHA-II, none class III or IV/HF in HCM-DM: 50% of the HCM-DM group were classified as NYHA-I, 45% NYHA-II, and 5% NYHA-III. Significant ↓myocardial blood flow and ↓myocardial perfusion reserve in HCM-DM compared with HCM.Significant ↓plasma Cr/ATP in HCM-DM compared with HCM.Significant ↓Extracellular Matrix in HCM-DM compared with HCM.Correlation between the stress myocardial blood flow and myocardial scar percentage was detected in the two groups. Matched: Age, Sex, ethnicity, GFR, baseline HR and BP, TG, Familial history of SCD, NYHA function class, medications (except statins and ACEi)Unmatched:Use of Statins and ACEi (was frequent in DM-HCM), BMI (patients with HCM-DM had higher BMI compared with HCM group), HDL, LDL, cholesterol Patients with CAD, cardiac surgery, tobacco smoking, amyloidosis, permanent AF, moderate or above valvular heart disease, eGFR<30 (mL/min/1.73 m2), and contraindications to CMR For the diabetes cohorts, patients with any other forms of diabetes than T2DM. Mekhaimar et al 2022 (5)National inpatient sample (NIS) databaseRetrospective cohort 8520/20 555All patients were hospitalised due to HF.FUD: 10-year time frame (2005–2015).AgeHCM-DM: 68.99 (13.97)HCM: 70.44 (16.66)BMI:HCM-DM: 29% had obesityHCM: 13.8% had obesityDiabetes duration: NRNone HCM-DM hospitalised for HF had significantly lower in-hospital mortality (3.9%) compared with HCM group (3.3%) even after adjustment for characteristics differ between two groups. HCM-DM had a lower adjusted risk of AF and VF compared with HCM alone. In-hospital mortality increased by almost eightfold in those aged>85 years and females compared with males.Obesity, CAD and CKD were associated with higher rates of cardiogenic shock.Patients aged 55–74 had a ↑risk of developing VF than those younger than 55.Among cardiovascular risk factors, obesity was the strongest predictor ofdeveloping AF Matched: Age, SmokingUnmatched: Obesity, HTN, dyslipidaemia, CKD, peripheral vascular disease, CAD Patients with missed data including age, gender, mortality, length of hospitalisation and charges. Lee et al 2022 (4)Korean NHIS databaseProspective cohort 1327/8556FUD: 5.9±2.5 yearsAgeHCM-DM: 63.8±10.9HCM: 57.7±13.3BMI:HCM-DM: NRHCM: NRDiabetes duration: ≥5 yearsNone HCM-DM had a significantly higher incidence rate of all-cause death (22%) compared with HCM group (13.9%).No significant difference in cardiovascular mortality between the HCM-DM and HCM group.HCM-DM had significantly higher non-cardiovascular mortality rates (13.7 vs 6.91 per 1000 person-year) including deaths due to cancer or respiratory causes. After adjustment for age, sex and comorbidities, HCM-DM was independently associated with a 3.5-fold higher risk of ESRD progression and 15% higher risk of incident HF. The association of HCM-DM with incident coronary events and cardiovascular death, lost statistical significance after adjustment for comorbidities, although there was a tendency for increased all-cause mortality with DM. Non-insulin treated DM was independently associated with ESRD progression, while insulin-treated DM was independently associated with an even higher risk of ESRD progression, incident HF and all-cause death, but not coronary events or cardiovascular death. Matched: NonUnmatched: Age, HTN, CAD, stroke, CKD (all had higher incident rate in HCM-DM compared with HCM). HCM-DM were significantly older than HCM group. Age<20 years,Subjects with the diagnosis of type I DM, previous history of HF or ESRD, and with missing variables Wasserstrum et al 2018 (6)Spain and IsraelProspective cohort 194/100FUD: 121 (82–174) months(10 years)AgeHCM-DM: 63 (56–72)HCM: 63 (55–71)BMI:HCM-DM: 30.1 (±4.1)HCM: 30 (±4.4)Diabetes duration: NR Significant ↑incidence of LAD>40 mm, diastolic dysfunction (any grade), SPAP>45 mm Hg, and moderate to severe mitral regurgitation in HCM-DM compared with HCM group. Significant ↓incidence of NYHA-I in HCM-DM (13%) compared with HCM (39%).↓ Objectively measured exercise capacity in HCM-DM compared with HCM group.↑ Prevalence of AF in HCM-DM (48%) compared with HCM (31%), but there were no differences in the prevalence of cerebral ischaemic events (7% vs 9%). Significant ↑rate of 15 year mortality in HCM-DM (22%) compared with HCM (15%). There was no difference in the reported appropriate ICD therapy (2% per group), reported sudden cardiac death (2% per group), or heart transplantation (0% vs 2%) in patients with or without DM. Matched: Age, BMI, HTN, hyperlipidaemia, smoking, CAD, CKD, COPD, familial history of SCD and HCM, pacemaker, implanted defibrillatorUnmatched: None Patients with infiltrative disease and uncontrolled HTN. *HCM-DM had significantly lower GFR than HCM; (however, mean GFR for HCM-DM was 96.7 mL/min).BMI, body mass index; CAD, coronary artery disease; CAG, coronary angiography; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CO, cardiac output; CTA, coronary computed angiography; ESRD, end-stage-renal disease; FBS, fasting blood glucose; FUD, follow-ep duration; GCS, global circumferential strain; GFR, glomerular filtration rate; GLS, global longitudinal strain; GRS, global radial strain; HbA1C, hemoglobin A1c; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter defibrillator; LAD, left atrial diameter; LGE, late gadolinium enhancement; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, myocardial infarction; NR, not reported; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCM, obstructive HCM; SCD, sudden cardiac death; SPAP, systolic pulmonary artery pressure; SV, stroke volume; SVT, supraventricular tachycardia. Included studies’ characteristics Badran et al 2024 (3) Badran et al 2024 (3) Egypt Egypt Prospective cohort Prospective cohort FUD: FUD: AgeHCM-DM: 47±17HCM: 44±14 Age HCM-DM: 47±17 HCM: 44±14 BMI: BMI: Diabetes duration: Diabetes duration: Significant ↓ E’ wave in HCM-DM compared with HCM group. Significant ↓ E’ wave in HCM-DM compared with HCM group. Significant ↓LV-GLS (less negative) in HCM-DM compared with HCM. Significant ↓LV-GLS (less negative) in HCM-DM compared with HCM. Significant ↓LV peak systolic global strain rate (less negative) in HCM-DM compared with HCM. Significant ↓LV peak systolic global strain rate (less negative) in HCM-DM compared with HCM. Significant ↓peak atrial diastolic and ↓LV early diastolic strain rate in HCM-DM compared with HCM. Significant ↓peak atrial diastolic and ↓LV early diastolic strain rate in HCM-DM compared with HCM. ↑Mortality rate:HCM-DM: 10.6%,HCM: 7.5%(no significant difference) ↑Mortality rate: HCM-DM: 10.6%, HCM: 7.5% (no significant difference) Significant ↑hospitalisation rate in HCM-DM (44.7%) compared with HCM (19.5%) Significant ↑hospitalisation rate in HCM-DM (44.7%) compared with HCM (19.5%) LV-GLS, LV peak systolic global strain rate and peak atrial diastolic strain rate in HCM-DM were inversely correlated to HbA1c and duration of diabetes. LV-GLS, LV peak systolic global strain rate and peak atrial diastolic strain rate in HCM-DM were inversely correlated to HbA1c and duration of diabetes. Matched: Age, sex, BP, baseline HR, familial HCM, NYHA function class, HCM phenotype Matched: Age, sex, BP, baseline HR, familial HCM, NYHA function class, HCM phenotype Unmatched: HTN was significantly higher in HCM-DM than HCM group. Unmatched: HTN was significantly higher in HCM-DM than HCM group. Poor acoustic window, other myocardium disease, arrhythmia, previous cardiac surgery, cardiac devices, valvular heart disease and evidence of CAD. Poor acoustic window, other myocardium disease, arrhythmia, previous cardiac surgery, cardiac devices, valvular heart disease and evidence of CAD. Wang et al 2024 (8) Wang et al 2024 (8) China China Retrospective cohort Retrospective cohort FUD: FUD: Age Age BMI:HCM-DM: 25.0±4.1-HCM: 25.4±4.1 BMI: HCM-DM: 25.0±4.1-HCM: 25.4±4.1 Diabetes duration: NR Diabetes duration: NR Prevalence of LAD>45mm:HCM-DM: 45.3%HCM: 33.3% (no significant difference) Prevalence of LAD>45mm: HCM-DM: 45.3% HCM: 33.3% (no significant difference) Significant ↑LVOT pressure gradient in HCM-DM compared with HCM. Significant ↑LVOT pressure gradient in HCM-DM compared with HCM. ↑Prevalence of NSVT, SVT and AF in HCM-DM compared with HCM. ↑Prevalence of NSVT, SVT and AF in HCM-DM compared with HCM. ↑FBS and HbA1C in patients with SVT, NSVT and AF compared with HCM-DM without arrhythmias. ↑FBS and HbA1C in patients with SVT, NSVT and AF compared with HCM-DM without arrhythmias. T2DM, IVST and symptom of amaurosis were independent risk factors for SVT after adjusting for age, sex and BMI. T2DM, IVST and symptom of amaurosis were independent risk factors for SVT after adjusting for age, sex and BMI. T2DM and LAD>45 mm were independent risk factors for AF after adjusting for age, sex and BMI. T2DM and LAD>45 mm were independent risk factors for AF after adjusting for age, sex and BMI. T2DM and history of syncope were independent risk factors for NSVT after adjusting for age, sex and BMI. T2DM and history of syncope were independent risk factors for NSVT after adjusting for age, sex and BMI. Matched: Age, sex, BMI, baseline HR, serum BNP, serum creatine, hyperlipidaemia, HTN, medication Matched: Age, sex, BMI, baseline HR, serum BNP, serum creatine, hyperlipidaemia, HTN, medication Unmatched: familial HCM and GFR* Unmatched: familial HCM and GFR* Not mentioned Not mentioned Hajouli et al 2024 (4) Hajouli et al 2024 (4) TriNetX database TriNetX database Retrospective cohort Retrospective cohort FUD: FUD: BMI: BMI: Diabetes duration: NR Diabetes duration: NR Significant ↓LVEF in HCM-DM compared with HCM group. Significant ↓LVEF in HCM-DM compared with HCM group. Non-significant ↑LAD in HCM-DM compared with HCM group. Non-significant ↑LAD in HCM-DM compared with HCM group. Significant ↑mortality rate in Significant ↑mortality rate in Significant ↑incidence of new-onset HF in HCM-DM (15.85%) compared with HCM (12.36%). Significant ↑incidence of new-onset HF in HCM-DM (15.85%) compared with HCM (12.36%). AF rate: AF rate: Survival analysis against the Survival analysis against the Matched: Sex, COPD, ESRD, HTN, CAD, Smoking, familial HCM, familial history of SCD, PH, arrhythmias, medication, GFR Matched: Sex, COPD, ESRD, HTN, CAD, Smoking, familial HCM, familial history of SCD, PH, arrhythmias, medication, GFR Unmatched: Unmatched: Patients with mitral Patients with mitral Yu et al2024 (7) Yu et al2024 (7) China China Retrospective cohort Retrospective cohort FUD: FUD: Age Age BMI: BMI: Diabetes duration: NR Diabetes duration: NR Significant ↓LVEDV, ↓SV, ↓LVEF, ↓CO, ↓LV-GLS, ↓LV-GRS, ↓LV-GCS, ↓LA-reservoir strain, ↓LA peak positive strain rate, ↓LA conduction function volume in HCM-DM compared with HCM group. Significant ↓LVEDV, ↓SV, ↓LVEF, ↓CO, ↓LV-GLS, ↓LV-GRS, ↓LV-GCS, ↓LA-reservoir strain, ↓LA peak positive strain rate, ↓LA conduction function volume in HCM-DM compared with HCM group. ↑LGE in HCM-DM compared with HCM group. ↑LGE in HCM-DM compared with HCM group. Significant ↑prevalence of AF in HCM-DM (18%) compared with HCM (9%). Significant ↑prevalence of AF in HCM-DM (18%) compared with HCM (9%). Comorbidity with T2DM was significantly associated with ↓LVEF, ↓GRS, ↑GCS, ↑GLS, ↓LA-reservoir strain and ↓LA peak positive strain rate. Comorbidity with T2DM was significantly associated with ↓LVEF, ↓GRS, ↑GCS, ↑GLS, ↓LA-reservoir strain and ↓LA peak positive strain rate. T2DM was an independent predictor of a low LVEF impaired LV-GLS. T2DM was an independent predictor of a low LVEF impaired LV-GLS. Matched: Maximal wall thickness, Matched: Maximal wall thickness, Unmatched: Unmatched: A history of MI, significant coronary arterial stenosis (≥ 50%) on invasive CAG or CTA A history of MI, significant coronary arterial stenosis (≥ 50%) on invasive CAG or CTA History of septal reduction therapy; History of septal reduction therapy; Concomitant uncontrolled Concomitant uncontrolled Jex et al 2022 (3) Jex et al 2022 (3) UK UK Prospective cohort Prospective cohort FUD: 2 years FUD: 2 years Age Age BMI: BMI: Diabetes duration: NR Diabetes duration: NR Significant ↑LVM, ↑LVMI, ↑LVM/LVEDV ratio, ↑LVPWT, ↑LA volume in HCM-DM compared with HCM group. Significant ↑LVM, ↑LVMI, ↑LVM/LVEDV ratio, ↑LVPWT, ↑LA volume in HCM-DM compared with HCM group. Significant ↓LVESV, ↓LV-SV, ↓RV-SV, ↓LVEF, ↓LV-GLS, ↓ Peak circumferential diastolic strain rate in HCM-DM compared with HCM group. Significant ↓LVESV, ↓LV-SV, ↓RV-SV, ↓LVEF, ↓LV-GLS, ↓ Peak circumferential diastolic strain rate in HCM-DM compared with HCM group. Significant ↑prevalence of stroke (TIA) in HCM-DM compared with HCM group. Significant ↑prevalence of stroke (TIA) in HCM-DM compared with HCM group. HF in isolated HCM: HF in isolated HCM: Significant ↓myocardial blood flow and ↓myocardial perfusion reserve in HCM-DM compared with HCM. Significant ↓myocardial blood flow and ↓myocardial perfusion reserve in HCM-DM compared with HCM. Significant ↓plasma Cr/ATP in HCM-DM compared with HCM. Significant ↓plasma Cr/ATP in HCM-DM compared with HCM. Significant ↓Extracellular Matrix in HCM-DM compared with HCM. Significant ↓Extracellular Matrix in HCM-DM compared with HCM. Correlation between the stress myocardial blood flow and myocardial scar percentage was detected in the two groups. Correlation between the stress myocardial blood flow and myocardial scar percentage was detected in the two groups. Matched: Age, Sex, ethnicity, GFR, baseline HR and BP, TG, Familial history of SCD, NYHA function class, medications (except statins and ACEi) Matched: Age, Sex, ethnicity, GFR, baseline HR and BP, TG, Familial history of SCD, NYHA function class, medications (except statins and ACEi) Unmatched: Unmatched: Patients with CAD, cardiac surgery, tobacco smoking, amyloidosis, permanent AF, moderate or above valvular heart disease, eGFR<30 (mL/min/1.73 m2), and contraindications to CMR Patients with CAD, cardiac surgery, tobacco smoking, amyloidosis, permanent AF, moderate or above valvular heart disease, eGFR<30 (mL/min/1.73 m2), and contraindications to CMR For the diabetes cohorts, patients with any other forms of diabetes than T2DM. For the diabetes cohorts, patients with any other forms of diabetes than T2DM. Mekhaimar et al 2022 (5) Mekhaimar et al 2022 (5) National inpatient sample (NIS) database National inpatient sample (NIS) database Retrospective cohort Retrospective cohort FUD: 10-year time frame (2005–2015). FUD: 10-year time frame (2005–2015). AgeHCM-DM: 68.99 (13.97)HCM: 70.44 (16.66) Age HCM-DM: 68.99 (13.97) HCM: 70.44 (16.66) BMI: BMI: Diabetes duration: NR Diabetes duration: NR HCM-DM hospitalised for HF had significantly lower in-hospital mortality (3.9%) compared with HCM group (3.3%) even after adjustment for characteristics differ between two groups. HCM-DM hospitalised for HF had significantly lower in-hospital mortality (3.9%) compared with HCM group (3.3%) even after adjustment for characteristics differ between two groups. HCM-DM had a lower adjusted risk of AF and VF compared with HCM alone. HCM-DM had a lower adjusted risk of AF and VF compared with HCM alone. In-hospital mortality increased by almost eightfold in those aged>85 years and females compared with males. In-hospital mortality increased by almost eightfold in those aged>85 years and females compared with males. Obesity, CAD and CKD were associated with higher rates of cardiogenic shock. Obesity, CAD and CKD were associated with higher rates of cardiogenic shock. Patients aged 55–74 had a ↑risk of developing VF than those younger than 55. Patients aged 55–74 had a ↑risk of developing VF than those younger than 55. Among cardiovascular risk factors, obesity was the strongest predictor of Among cardiovascular risk factors, obesity was the strongest predictor of Matched: Age, Smoking Matched: Age, Smoking Unmatched: Obesity, HTN, dyslipidaemia, CKD, peripheral vascular disease, CAD Unmatched: Obesity, HTN, dyslipidaemia, CKD, peripheral vascular disease, CAD Patients with missed data including age, gender, mortality, length of hospitalisation and charges. Patients with missed data including age, gender, mortality, length of hospitalisation and charges. Lee et al 2022 (4) Lee et al 2022 (4) Korean NHIS database Korean NHIS database Prospective cohort Prospective cohort FUD: 5.9±2.5 years FUD: 5.9±2.5 years Age Age BMI: BMI: Diabetes duration: ≥5 years Diabetes duration: ≥5 years HCM-DM had a significantly higher incidence rate of all-cause death (22%) compared with HCM group (13.9%). HCM-DM had a significantly higher incidence rate of all-cause death (22%) compared with HCM group (13.9%). No significant difference in cardiovascular mortality between the HCM-DM and HCM group. No significant difference in cardiovascular mortality between the HCM-DM and HCM group. HCM-DM had significantly higher non-cardiovascular mortality rates (13.7 vs 6.91 per 1000 person-year) including deaths due to cancer or respiratory causes. HCM-DM had significantly higher non-cardiovascular mortality rates (13.7 vs 6.91 per 1000 person-year) including deaths due to cancer or respiratory causes. After adjustment for age, sex and comorbidities, HCM-DM was independently associated with a 3.5-fold higher risk of ESRD progression and 15% higher risk of incident HF. After adjustment for age, sex and comorbidities, HCM-DM was independently associated with a 3.5-fold higher risk of ESRD progression and 15% higher risk of incident HF. The association of HCM-DM with incident coronary events and cardiovascular death, lost statistical significance after adjustment for comorbidities, although there was a tendency for increased all-cause mortality with DM. The association of HCM-DM with incident coronary events and cardiovascular death, lost statistical significance after adjustment for comorbidities, although there was a tendency for increased all-cause mortality with DM. Non-insulin treated DM was independently associated with ESRD progression, while insulin-treated DM was independently associated with an even higher risk of ESRD progression, incident HF and all-cause death, but not coronary events or cardiovascular death. Non-insulin treated DM was independently associated with ESRD progression, while insulin-treated DM was independently associated with an even higher risk of ESRD progression, incident HF and all-cause death, but not coronary events or cardiovascular death. Matched: Non Matched: Non Unmatched: Age, HTN, CAD, stroke, CKD (all had higher incident rate in HCM-DM compared with HCM). HCM-DM were significantly older than HCM group. Unmatched: Age, HTN, CAD, stroke, CKD (all had higher incident rate in HCM-DM compared with HCM). HCM-DM were significantly older than HCM group. Age<20 years, Age<20 years, Subjects with the diagnosis of type I DM, previous history of HF or ESRD, and with missing variables Subjects with the diagnosis of type I DM, previous history of HF or ESRD, and with missing variables Wasserstrum et al 2018 (6) Wasserstrum et al 2018 (6) Spain and Israel Spain and Israel Prospective cohort Prospective cohort FUD: 121 (82–174) months FUD: 121 (82–174) months Age Age BMI: BMI: Diabetes duration: NR Diabetes duration: NR Significant ↑incidence of LAD>40 mm, diastolic dysfunction (any grade), SPAP>45 mm Hg, and moderate to severe mitral regurgitation in HCM-DM compared with HCM group. Significant ↑incidence of LAD>40 mm, diastolic dysfunction (any grade), SPAP>45 mm Hg, and moderate to severe mitral regurgitation in HCM-DM compared with HCM group. Significant ↓incidence of NYHA-I in HCM-DM (13%) compared with HCM (39%). Significant ↓incidence of NYHA-I in HCM-DM (13%) compared with HCM (39%). ↓ Objectively measured exercise capacity in HCM-DM compared with HCM group. ↓ Objectively measured exercise capacity in HCM-DM compared with HCM group. ↑ Prevalence of AF in HCM-DM (48%) compared with HCM (31%), but there were no differences in the prevalence of cerebral ischaemic events (7% vs 9%). ↑ Prevalence of AF in HCM-DM (48%) compared with HCM (31%), but there were no differences in the prevalence of cerebral ischaemic events (7% vs 9%). Significant ↑rate of 15 year mortality in HCM-DM (22%) compared with HCM (15%). Significant ↑rate of 15 year mortality in HCM-DM (22%) compared with HCM (15%). There was no difference in the reported appropriate ICD therapy (2% per group), reported sudden cardiac death (2% per group), or heart transplantation (0% vs 2%) in patients with or without DM. There was no difference in the reported appropriate ICD therapy (2% per group), reported sudden cardiac death (2% per group), or heart transplantation (0% vs 2%) in patients with or without DM. Matched: Age, BMI, HTN, hyperlipidaemia, smoking, CAD, CKD, COPD, familial history of SCD and HCM, pacemaker, implanted defibrillator Matched: Age, BMI, HTN, hyperlipidaemia, smoking, CAD, CKD, COPD, familial history of SCD and HCM, pacemaker, implanted defibrillator Unmatched: None Unmatched: None Patients with infiltrative disease and uncontrolled HTN. Patients with infiltrative disease and uncontrolled HTN. HCM-DM had significantly lower GFR than HCM; (however, mean GFR for HCM-DM was 96.7 mL/min). BMI, body mass index; CAD, coronary artery disease; CAG, coronary angiography; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CO, cardiac output; CTA, coronary computed angiography; ESRD, end-stage-renal disease; FBS, fasting blood glucose; FUD, follow-ep duration; GCS, global circumferential strain; GFR, glomerular filtration rate; GLS, global longitudinal strain; GRS, global radial strain; HbA1C, hemoglobin A1c; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter defibrillator; LAD, left atrial diameter; LGE, late gadolinium enhancement; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, myocardial infarction; NR, not reported; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCM, obstructive HCM; SCD, sudden cardiac death; SPAP, systolic pulmonary artery pressure; SV, stroke volume; SVT, supraventricular tachycardia. Risk of bias assessment Overall risk was low to moderate (~15%), with moderate bias mainly in confounding and missing data. Four studies had inadequate matching for BMI,3–5 7 two for hypertension (HTN),3 7 one for coronary artery disease (CAD)7 and Lee et al6 showed mismatching across multiple factors including age, CAD, chronic kidney disease, HTN and stroke. One study had high risk in participant selection due to missing exclusion criteria,10 and Mekhaimar et al7 had moderate risk by including only patients with HF. Failure to report DM duration in five studies4 5 8–104 contributed to moderate bias from missing data. Wasserstrum et al8 reported echo parameters as incidence rates rather than measured values, affecting reporting bias. Figures 2 and 3 summarise the ROBINS-I assessments. Risk of bias assessment. Risk of bias assessment for included studies using the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool. Each domain (D1–D7) is evaluated for potential bias, with green sign indicating a low risk of bias. The overall risk of bias for each study is also summarised. Overall risk of bias summary. Summary of the overall risk of bias across all studies, categorised as low, moderate or serious risk. The percentage of studies falling into each risk category is displayed for each domain and overall. GRADE assessment In the GRADE assessment, certainty was high for all-cause mortality, HF and AF; moderate for left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV), left ventricular global longitudinal strain (LV-GLS) and left atrial diameter (LAD); and low for left ventricular end systolic diameter (LVESD), interventricular septal thickness (IVST) and left ventricular mass (LVM). Lower certainty was mainly due to few studies, substantial heterogeneity and potential biases. Table 2 presents full details, and online supplemental table S2 outlines reasons for downgrading or upgrading certainty per GRADE and Centers for Disease Control and Prevetion-Advisory Committee on Immunization Practices (CDC-ACIP) guidance (online supplemental S2). As per ROBINS-I, all outcomes were initially rated high. Table 2GRADE assessmentAssessmentSummary of findingsOutcome(study number)Risk of biasLimitationInconsistencyIndirectnessImprecisionConsiderationsOR (95% CI)SMD (95% CI)Certainty of evidenceClinical outcomesAll causes of death(n=5)Low*LowModerate†LowLowExcluding Mekhaimar et al (2022) reduced heterogeneity to 0%.1.429 (1.236 to 1.652)1.533 (1.433 to 1.640)‡⊕⊕⊕⊕HighHeart failure(n=4)LowModerate§LowLowLowNone1.34 (1.250 to 1.439)⊕⊕⊕ΟModerateAtrial fibrillation(n=5)LowLowLowLowLowNone1.368 (1.173 to 1.595)⊕⊕⊕⊕HighCardiac functionLVEF(n=6)Moderate¶LowHigh¶**LowModerate¶††Excluding Yu et al (2024) resulted in reduction of heterogeneity to 0%. −0.114 (−0.331 to 0.102)−0.005 (−0.113 to 0.103)‡ ⊕⊕⊕ΟModerateLVEDV(n=4)LowModerate§LowLowLowNone−0.263 (−0.410 to 0.117)⊕⊕⊕ΟModerateLVESD(n=3)Low‡‡High§§Moderate†LowHigh††Excluding Yu et al (2024) reduces the heterogeneity to 0% but did not change the statistical insignificance. −0.018 (−0.335 to 0.298)−0.175 (−0.364 to 0.014)‡ ⊕⊕ΟΟLowLV-GLS(n=3)LowHigh§§LowLowLowNone0.532 (0.300 to 0.765)⊕⊕⊕ΟModerateLVM(n=3)LowHigh§§LowLowHigh††None0.113 (−0.116 to 0.341)⊕⊕⊕ΟModerateLAD(n=4)High¶¶Moderate§LowLowLowExcluding Hajouli et al (2024) reduced the heterogeneity to 0% and changed the significant results into insignificancy.0.185 (0.161 to 0.208)−0.023 (−0.252 to 0.205)‡⊕⊕⊕ΟModerateLV peak systolic global strain rate(n=3)Low***High§§Moderate†LowLowExcluding Badran et al (2024) reduced heterogeneity to 0%.0.603 (0.225 to 0.982)0.800 (0.440 to 1.161)‡⊕⊕⊕ΟModerateIVST(n=5)LowLowLowLowHigh††None0.104 (−0.038 to 0.247)⊕⊕⊕ΟModerateLVOT gradient pressure(n=2)LowHigh§§LowLowLowNone0.306 (0.101 to 0.512)⊕⊕⊕ΟModerate*The study by Mekhaimar et al (2022) reported that all cases of HCM had heart failure, which introduced a high potential for risk of bias and contributed to the high level of heterogeneity. A sensitivity analysis was conducted by excluding this study did not change the significance of the findings.†The level of heterogeneity is moderate to high.‡Result of post-sensitivity analysis.§The number of studies is low.¶The study conducted by Yu et al (2024) was found to have a high risk of bias, due to the different range of results reported. A sensitivity analysis by excluding this study changed the statistical insignificance of the summary estimate to a significant result and reduced the level of heterogeneity to 0%.**The level of heterogeneity is high.††CI of the summary estimate included 0.‡‡The study conducted by Yu et al (2024) was found to have a high risk of bias, due to the different range of results reported. A sensitivity analysis by excluding this study did not change the statistical insignificance of the summary estimate.§§The number of studies is very low.¶¶The study conducted by Hajouli et al (2024) was found to have a high risk of bias, likely due to the wide variability in the range of results reported. A sensitivity analysis was conducted by excluding this study, which changed the statistical significance of the results into insignificant findings.***The study conducted by Badran et al (2024) was found to have a high risk of bias, due to the different range of results reported. A sensitivity analysis by excluding this study did not change the direction or statistical significance of the results.DM, diabetes mellitus; HCM, hypertrophic cardiomyopathy; IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; LV-GLS, left ventricular global longitudinal strain; LVM, left ventricular mass; LVOT, left ventricular outlet tract; SMD, standardised mean difference. GRADE assessment −0.114 (−0.331 to 0.102) −0.114 (−0.331 to 0.102) −0.005 (−0.113 to 0.103)‡ −0.005 (−0.113 to 0.103)‡ −0.018 (−0.335 to 0.298) −0.018 (−0.335 to 0.298) −0.175 (−0.364 to 0.014)‡ −0.175 (−0.364 to 0.014)‡ The study by Mekhaimar et al (2022) reported that all cases of HCM had heart failure, which introduced a high potential for risk of bias and contributed to the high level of heterogeneity. A sensitivity analysis was conducted by excluding this study did not change the significance of the findings. The level of heterogeneity is moderate to high. Result of post-sensitivity analysis. The number of studies is low. The study conducted by Yu et al (2024) was found to have a high risk of bias, due to the different range of results reported. A sensitivity analysis by excluding this study changed the statistical insignificance of the summary estimate to a significant result and reduced the level of heterogeneity to 0%. The level of heterogeneity is high. CI of the summary estimate included 0. The study conducted by Yu et al (2024) was found to have a high risk of bias, due to the different range of results reported. A sensitivity analysis by excluding this study did not change the statistical insignificance of the summary estimate. The number of studies is very low. The study conducted by Hajouli et al (2024) was found to have a high risk of bias, likely due to the wide variability in the range of results reported. A sensitivity analysis was conducted by excluding this study, which changed the statistical significance of the results into insignificant findings. The study conducted by Badran et al (2024) was found to have a high risk of bias, due to the different range of results reported. A sensitivity analysis by excluding this study did not change the direction or statistical significance of the results. DM, diabetes mellitus; HCM, hypertrophic cardiomyopathy; IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; LV-GLS, left ventricular global longitudinal strain; LVM, left ventricular mass; LVOT, left ventricular outlet tract; SMD, standardised mean difference. Result of synthesis Clinical outcomes All-cause mortality Pooled analysis showed higher all-cause mortality in HCM-DM versus HCM (OR=1.42, 95% CI 1.23 to 1.65, p<0.001, I²=64%) (figure 4). Excluding Mekhaimar et al7 eliminated heterogeneity (I²=0%) and increased the effect (OR=1.53, 95% CI 1.43 to 1.64, p<0.001). In patients>50 years, mortality odds were similar (OR=1.42, 95% CI 1.22 to 1.66, p<0.001, I²=70%), with heterogeneity dropping to 0% and effect size rising to 1.53 after excluding Mekhaimar et al.7 Sensitivity analysis (‘one study removed’) found no outliers, indicating stability of results (online supplemental S5). Forest plot for all-cause mortality. Forest plot showing the ORs and 95% CIs for all-cause mortality in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. The meta-analysis demonstrates a significantly higher risk of all-cause mortality in patients with HCM-DM (OR=1.42, 95% CI 1.23 to 1.65, p<0.001). Heart failure HF was more frequent in HCM-DM than controls (OR=1.34, 95% CI 1.25 to 1.43, p<0.001; I²=0%) (figure 5). Similar results were seen in patients>50 years (OR=1.34, 95% CI 1.24 to 1.43, p<0.001; I²=0%) (table 3). Sensitivity analysis (‘one study removed’) detected no outliers, confirming result stability (online supplemental S5). Forest plot for heart failure. Forest plot displaying the ORs and 95% CIs for heart failure in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. The meta-analysis indicates a significantly higher risk of heart failure in patients with HCM-DM (OR=1.34, 95% CI 1.25 to 1.43, p<0.001). Table 3Result of synthesis of clinical outcomes and cardiac function indicesParametersNo. studiesNo. cases/eventNo. controls/eventEffectmodelOR (CI: 95%),SMD (CI: 95%)P valueHeterogeneityI2P value Long-term outcomes All-cause mortality Overall52472/24 2752882/44 597Random1.429 (1.236 to 1.652) <0.001 64%0.025Sensitivity analysis*41726/10 6402617/21 637Random1.533 (1.433 to 1.640) <0.001 0%0.989 Grouped by age <50 years15/4728/372–1.463 (0.536 to 3.992)–––>50 years42467/24 2282854/44 225Random1.429 (1.225 to 1.668) <0.001 70%Sensitivity analysis*31721/10 5932589/21 265Random1.533 (1.433 to 1.641) <0.001 0% Heart failure Overall41726/10 6402617/21 637Random1.34 (1.250 to 1.439) <0.001 0%0.904 Grouped by age <50 years15/4728/372–1.386 (0.719 to 2.673)–––>50 years31721/10 5932589/19 048Random1.341 (1.249 to 1.439) <0.001 0%0.757 Atrial fibrillation Overall5267/15971044/8956Random1.411 (1.077 to 1.848) <0.001 22%0.269 Grouped by age <50 years228/12022/195Random2.553 (1.372 to 4.751) 0.002 0%0.804>50 years3239/14771022/8761Random1.313 (1.121 to 1.539) 0.003 0%0.610 Grouped by BMI <30 kg/m2228/12022/195Random2.553 (1.372 to 4.751) 0.003 0%0.804>30 kg/m2251/12091/205Random1.051 (0.658 to 1.679)0.8350%0.942 Cardiac function LVEF Overall614 56615 060Random−0.114 (−0.331 to 0.102)0.30278%0.000Sensitivity analysis†514 52115 015Random−0.005 (−0.113 to 0.103)0.92629%0.226 Grouped by age <50 years2122522Random0.027 (−0.410 to 0.463)0.9050%0.932>50 years414 44414 536Random−0.216 (−0.538 to 0.105)0.18786%0.000Sensitivity analysis†314 39914 493Random−0.001 (−0.167 to 0.165)0.99151%0.065 Grouped by BMI <30 kg/m22122522Random−0.420 (−0.908 to 0.068)0.09290%0.000>30 kg/m2314 73914 164Random−0.016 (−0.404 to 0.371)0.93460%0.078 LVEDV Overall4267761Random−0.263 (−0.410 to –0.117) <0.001 0%0.631 LVESD Overall3192611Random−0.018 (−0.335 to 0.298)0.91067%0.378Sensitivity analysis†2147566Random−0.175 (−0.364 to 0.014)0.0690%0.789 LV-GLS Overall3112435Random0.579 (0.259 to 0.898) <0.001 38%0.198 LAD Overall414 39114 714Random0.185 (0.161 to 0.208) <0.001 29%0.235Sensitivity analysis‡3112435Random−0.023 (−0.252 to 0.205)0.8410%0.595 LVM Overall3112435Random0.113 (−0.116 to 0.341)0.3340%0.941 IVST Overall52877790.104 (−0.038 to 0.247)0.1632.9%0.390 LVOT pressure gradient Overall2122522Random0.306 (0.101 to 0.512) 0.004 0%0.599 LV peak systolic global strain rate Overall3112435Random0.603 (0.225 to 0.982) 0.002 54%0.112Sensitivity analysis†26563Random0.800 (0.440 to 1.161) <0.001 0%0.493*The study by Mekhaimar et al (2022) reported that all cases of HCM had heart failure, which introduced a high potential for risk of bias and contributed to the high level of heterogeneity. To address this, a sensitivity analysis was conducted by excluding this study, which resulted in a significant reduction in heterogeneity to 0%.†The study conducted by Yu et al (2024) was found to have a high risk of bias, due to the different range of results reported. To address this, a sensitivity analysis was conducted by excluding this study, which resulted in a significant reduction in heterogeneity to 0%.‡The study conducted by Hajouli et al (2024) was found to have a high risk of bias, likely due to the wide variability in the range of results reported. To address this, a sensitivity analysis was conducted by excluding this study, which resulted in a significant reduction in heterogeneity to 0%.BMI, body mass index; HCM, hypertrophic cardiomyopathy; IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; LV-GLS, left ventricular global longitudinal strain; LVM, left ventricular mass; LVOT, left ventricular outlet tract; SMD, standardised mean difference. Result of synthesis of clinical outcomes and cardiac function indices The study by Mekhaimar et al (2022) reported that all cases of HCM had heart failure, which introduced a high potential for risk of bias and contributed to the high level of heterogeneity. To address this, a sensitivity analysis was conducted by excluding this study, which resulted in a significant reduction in heterogeneity to 0%. The study conducted by Yu et al (2024) was found to have a high risk of bias, due to the different range of results reported. To address this, a sensitivity analysis was conducted by excluding this study, which resulted in a significant reduction in heterogeneity to 0%. The study conducted by Hajouli et al (2024) was found to have a high risk of bias, likely due to the wide variability in the range of results reported. To address this, a sensitivity analysis was conducted by excluding this study, which resulted in a significant reduction in heterogeneity to 0%. BMI, body mass index; HCM, hypertrophic cardiomyopathy; IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; LV-GLS, left ventricular global longitudinal strain; LVM, left ventricular mass; LVOT, left ventricular outlet tract; SMD, standardised mean difference. Atrial fibrillation AF prevalence was higher in HCM-DM than HCM alone (OR=1.41, 95% CI 1.07 to 1.84, p=0.012; I²=22%) (figure 6). Subgroup analysis showed stronger associations in younger patients (<50 years: OR=2.55, 95% CI 1.37 to 4.75, p<0.002; I²=0%) than older (>50 years: OR=1.31, 95% CI 1.12 to 1.53, p=0.003; I²=0%). AF odds were also higher in BMI<30 kg/m² (OR=2.55, 95% CI 1.37 to 4.75, p=0.003; I²=0%) but not in BMI≥30 kg/m² (OR=1.05, 95% CI 0.65 to 1.67, p=0.83; I²=0%) (table 3). Removing Lee et al6 rendered the pooled AF estimate non-significant (OR=1.60, 95% CI 0.89 to 2.84, p=0.11). Forest plot for atrial fibrillation. Forest plot illustrating the ORs and 95% CIs for atrial fibrillation in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. The meta-analysis shows a significantly higher risk of atrial fibrillation in patients with HCM-DM (OR=1.41, 95% CI 1.07 to 1.84, p=0.01). Cardiac function Left ventricular ejection fraction No significant difference in LVEF was observed between HCM-DM and HCM groups (SMD=−0.11, 95% CI −0.33 to 0.10, p=0.30; I²=78%) (figure 7). Excluding Yu et al9 reduced heterogeneity to 29% without altering significance (SMD=−0.005, 95% CI −0.113 to 0.103, p=0.926). Subgroup analyses by BMI (<30 kg/m²: SMD=−0.42, 95% CI −0.90 to 0.06, p=0.09, I²=90%; ≥30 kg/m²: SMD=−0.01, 95% CI −0.40 to 0.37, p=0.93, I²=60%) and age (<50 years: SMD=0.02, 95% CI −0.17 to 0.23, p=0.80, I²=0%; ≥50 years: SMD=−0.21, 95% CI −0.53 to 0.10, p=0.18, I²=86%) showed no significant differences. Sensitivity analysis using the ‘one study removed’ method confirmed robustness, with no outliers detected. Forest plot for left ventricular ejection fraction (LVEF). Forest plot presenting the standardised mean differences (SMD) and 95% CIs for LVEF in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. No significant difference in LVEF was observed between the two groups (SMD=−0.11, 95% CI −0.33 to 0.10, p=0.30). Left ventricular end-diastolic volume Meta-analysis of four studies showed smaller LVEDV in HCM-DM versus controls (SMD=−0.26, 95% CI −0.41 to –0.11, p<0.001; I²=0%) (figure 8). ‘One study removed’ analysis found no outliers, confirming result stability. Forest plot for left ventricular end-diastolic volume (LVEDV). Forest plot showing the standardised mean differences (SMD) and 95% CIs for LVEDV in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. The meta-analysis reveals a significantly smaller LVEDV in patients with HCM-DM (SMD=−0.26, 95% CI −0.41 to −0.11, p<0.001). Left ventricular end-systolic dimension LVESD did not differ between groups (SMD=−0.01, 95% CI −0.33 to 0.29, p=0.91; I²=67%). Excluding Yu et al9 produced similar results (SMD=−0.17, 95% CI −0.36 to 0.01, p=0.06; I²=0%), with no outliers detected. Left ventricular global longitudinal strain Meta-analysis of three studies showed lower (less negative) LV-GLS in HCM-DM (SMD=0.57, 95% CI 0.25 to 0.89, p<0.001; I²=38%) (figure 9). ‘One study removed’ analysis found no outliers, confirming stability. Forest plot for left ventricular global longitudinal strain (LV-GLS). Forest plot displaying the standardised mean differences (SMD) and 95% CIs for LV-GLS in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. The meta-analysis indicates a significant impairment in LV-GLS in patients with HCM-DM (SMD=0.57, 95% CI 0.25 to 0.89, p<0.001). Left atrial diameter LAD was larger in HCM-DM than HCM (SMD=0.18, 95% CI 0.16 to 0.20, p<0.001; I²=29%) (figure 10). Excluding Hajouli et al4 rendered the association non-significant (SMD=−0.02, 95% CI −0.25 to 0.20, p=0.84; I²=0%). Forest plot for left atrial diameter (LAD). Forest plot illustrating the standardised mean differences (SMD) and 95% CIs for LAD in patients with hypertrophic cardiomyopathy and diabetes mellitus (HCM-DM) compared with patients with HCM without DM. The meta-analysis shows a significant increase in LAD in patients with HCM-DM (SMD=0.18, 95% CI 0.16 to 0.20, p<0.001). Left ventricular mass and Interventricular septal thickness No significant differences were found for LVM (SMD=0.11, 95% CI −0.11 to 0.34, p=0.33; I²=0%) or IVST (SMD=0.10, 95% CI −0.03 to 0.24, p=0.16; I²=2.9%). ‘One study removed’ analysis detected no outliers, confirming consistency. LVOT pressure gradient Left ventricular outflow tract (LVOT) gradient was higher in HCM-DM than HCM (SMD=0.30, 95% CI 0.10 to 0.51, p=0.004; I²= 0%). LV peak systolic global strain rate Meta-analysis of three studies showed lower (less negative) strain rate in HCM-DM (SMD=0.60, 95% CI 0.22 to 0.98, p=0.002; I²=54%). Excluding Badran et al3 reduced heterogeneity to 0% and increased the effect (SMD=0.80, 95% CI 0.44 to 1.16, p<0.001). Excluding Yu et al9 rendered the result non-significant (SMD=0.59, 95% CI −0.05 to 1.24, p=0.07). Forest plots for subgroup and sensitivity analyses are in online supplemental S3 and S5. Publication bias Funnel plot analysis, Begg’s and Egger’s tests (online supplemental S4 document) were used to assess the publication bias. No significant publication bias was observed. Discussion In this meta-analysis of over 47 000 patients with HCM, coexisting DM identified a distinct higher-risk phenotype. DM was associated with significantly greater odds of all-cause mortality, HF and AF, with the AF signal strongest in patients younger than 50 years and attenuated in those with obesity. Imaging data showed smaller LVEDV and impaired GLS, while LVEF, LVM and IVST were not significantly different. Our effect estimates align with and extend prior registry data. For example, the Korean National Health Insurance cohort reported a 15% higher HF risk in HCM-DM, compared with a 34% increase in our pooled analysis.6 AF risk was similarly consistent with EUR-Observational HCM Registry findings, where each decade of age increased AF risk by approximately 68%, comparable to the impact of DM in our meta-analysis.14 15 The stronger association in younger, non-obese patients may reflect the absence of competing obesity-related arrhythmia mechanisms, allowing the arrhythmogenic effects of DM to emerge more clearly. Several mechanisms may underlie these adverse outcomes. Chronic hyperglycaemia promotes myocardial fibrosis, microvascular dysfunction and impaired energetics, amplifying the hypertrophic, diastolic and arrhythmogenic substrate of HCM.16 17 Insulin resistance and systemic inflammation accelerate atrial remodelling, consistent with the stronger AF signal in younger patients.18 Structurally, smaller LVEDV and larger left atrial diameter suggest reduced filling and chronic atrial pressure overload, while impaired GLS and lower strain rate indicate subclinical systolic dysfunction likely driven by metabolic stress and microvascular ischaemia.19 Cardiac function analysis demonstrated changes that, while modest in magnitude, are physiologically meaningful in HCM-DM. LV-GLS was significantly reduced (SMD≈0.58), a degree of impairment comparable to that seen in early-stage HF with preserved ejection fraction, indicating subclinical systolic dysfunction despite preserved EF. LAD was slightly but significantly larger (SMD≈0.2), consistent with incremental enlargement on pre-existing dilation; even small increases in atrial size may meaningfully raise arrhythmia risk, particularly when baseline enlargement is present.20 LVEDV was reduced, supporting impaired relaxation and diminished compliance, plausibly driven by myocardial fibrosis and microvascular dysfunction described in CMR studies.19 Concordantly, higher LVOT pressure gradients were observed in HCM-DM, likely reflecting the combined effects of smaller ventricular volumes, increased myocardial stiffness and augmented contractility associated with metabolic alterations.21 No significant differences emerged for LVEF, LVESD, LVM or IVST; however, heterogeneity for LVEF was high (I²≈78%), which may reflect differences in imaging methods, patient selection, diabetes severity and duration, and follow-up.22 A reduction in strain rate further reinforces the presence of subtle systolic impairment. Collectively, these findings argue for incorporating volumetric and strain-based assessments into risk stratification, closer rhythm and diastolic-function surveillance, and cautious use of preload-reducing therapies in susceptible patients. This meta-analysis could not stratify outcomes by obstructive versus non-obstructive HCM, as most studies did not report subtype-specific data. Available evidence, however, suggests that DM adversely affects both phenotypes.3 10 While obstruction adds pressure overload, diabetes amplifies diastolic dysfunction through myocardial fibrosis, altered titin phosphorylation and collagen crosslinking from advanced glycation end products.6 23 Prior studies have shown that, even after adjusting for comorbidities, patients with HCM-DM have higher rates of LV diastolic dysfunction, pulmonary HTN, significant mitral regurgitation and worse dyspnoea, without significant differences in LV wall thickness, cavity size, systolic function or outflow tract gradients.8 This supports the concept that the main myocardial impact of diabetes in HCM is the worsening of diastolic function rather than structural hypertrophy. Limitations and interpretation Interpretation should consider the small number of eligible studies, most of which are recent and observational, with variable follow-up durations and incomplete reporting of key variables such as DM duration, BMI and hemoglobin-A1c (HbA1c). Heterogeneity in imaging measures was high, and most studies did not stratify by obstructive versus non-obstructive HCM, limiting phenotype-specific conclusions. Given the observational design, these associations do not prove causality, and DM should be viewed as a clinically important risk marker rather than a proven causal determinant. Clinical and research implications These findings support closer rhythm and function surveillance in patients with HCM-DM, potential incorporation of DM into risk stratification models and attention to metabolic control as part of comprehensive care. Future research should include large prospective cohorts with standardised imaging, examine obstructive versus non-obstructive subtypes, and assess whether targeted metabolic interventions can modify arrhythmia and HF risk in this population. Conclusion This systematic review and meta-analysis highlights the significant impact of DM on the progression and outcomes of HCM, with higher rates of mortality, HF and arrhythmia compared with HCM in patients without DM. These findings suggest that DM contributes to structural and functional myocardial alterations, likely through increased fibrosis, vascular injury and reduced myocardial compliance, thereby worsening disease severity. Supplementary material